[1]
|
Zhao, H., Zhou, X. and Zhou, Y.H. (2020) Hepatitis B Vaccine Development and Implementation. Human Vaccines & Immunotherapeutics, 16, 1533-1544. https://doi.org/10.1080/21645515.2020.1732166
|
[2]
|
World Health Organi-zation Hepatitis B/Detail/Fact Sheets/News Room/Home. June 24 2022.
https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
|
[3]
|
Lozano, R., Naghavi, M., Foreman, K., et al. (2012) Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. The Lancet, 380, 2095-2128. https://doi.org/10.1016/S0140-6736(12)61728-0
|
[4]
|
Yeo, Y.H., Tseng, T.C., Hosaka, T., et al. (2020) Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. Clinical and Translational Gastroenterology, 11, e00196.
https://doi.org/10.14309/ctg.0000000000000196
|
[5]
|
Taniguchi, H., Iwasaki, Y., Aimi, M., et al. (2020) Clinical Features of Chronic Hepatitis B Patients with Low Hepatitis B Surface Antigen Levels and Determinants of Hepatitis B Surface Antigen Seroclearance. JGH Open, 4, 698-706.
https://doi.org/10.1002/jgh3.12321
|
[6]
|
Zhu, L., Zhai, X., Wang, Q., et al. (2018) Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance and Seroconversion in Hepatitis B e Antigen-Negative Chronic Infection Patients: A Population-Based Prospective Cohort. Journal of Viral Hepatitis, 25, 1588-1598. https://doi.org/10.1111/jvh.12978
|
[7]
|
Heathcote, E.J., Marcellin, P., Buti, M., et al. (2011) Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B. Gastroenterology, 140, 132-143. https://doi.org/10.1053/j.gastro.2010.10.011
|
[8]
|
Hsu, Y.C., Yeh, M.L., Wong, G.L.H., et al. (2021) Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. The Journal of Infectious Diseases, 224, 1890-1899.
https://doi.org/10.1093/infdis/jiab241
|
[9]
|
Caviglia, G.P., Troshina, Y., Garro, E., et al. (2021) Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Vi-rus Infection Treated with Nucleos (t) Ide Analogues: A Real-World Study. Journal of Clinical Medicine, 10, 3308. https://doi.org/10.3390/jcm10153308
|
[10]
|
Suzuki, F., Hosaka, T., Suzuki, Y., et al. (2019) Long-Term Outcome of Entecavir Treatment of Nucleos (t) Ide Analogue-Naïve Chronic Hepatitis B Patients in Japan. Journal of Gastroenterol-ogy, 54, 182-193.
https://doi.org/10.1007/s00535-018-1502-y
|
[11]
|
Zhao, H., Kurbanov, F., Wan, M.B., et al. (2007) Genotype B and Younger Patient Age Associated with Better Response to Low-Dose Therapy: A Trial with Pegylated/Nonpegylated In-terferon-α-2b for Hepatitis Be Antigen—Positive Patients with Chronic Hepatitis B in China. Clinical Infectious Diseases, 44, 541-548.
https://doi.org/10.1086/511042
|
[12]
|
Zhou, Y., Yan, R., Ru, G.Q., et al. (2019) Pegylated-Interferon Consolidation Treatment versus Nucleos (t) Ide Analogue Consolidation Treatment in Non-Cirrhotic Hepatitis B Patients with Hepatitis B e Antigen Seroconversion: An Open-Label Pilot trial. Hepatology International, 13, 422-430. https://doi.org/10.1007/s12072-019-09957-0
|
[13]
|
Sarin, S.K., Kumar, M., Lau, G.K., et al. (2016) Asian-Pacific Clinical Practice Guidelines on the Management of Hepatitis B: A 2015 Update. Hepatology International, 10, 1-98. https://doi.org/10.1007/s12072-015-9675-4
|
[14]
|
宁琴, 陈良, 陈新月, 等. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 中华临床感染病杂志, 2019, 12(4): 241-252.
|
[15]
|
Ahn, S.H., Marcellin, P., Ma, X., et al. (2018) Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate plus Peginterferon alfa-2a: Week 120 Analysis. Digestive Diseases and Sciences, 63, 3487-3497.
https://doi.org/10.1007/s10620-018-5251-9
|
[16]
|
Jun, D.W., Ahn, S.B., Kim, T.Y., et al. (2018) Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e An-tigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study). Chinese Medical Journal, 131, 1645-1651.
https://doi.org/10.4103/0366-6999.235880
|
[17]
|
喻一奇, 陈少隆, 张文宏. 核苷和核苷酸类药物联合聚乙二醇干扰素治疗慢性乙型肝炎的研究进展[J]. 临床肝胆病杂志, 2015, 31(9): 1513-1519.
|
[18]
|
Yoshida, K., Enomoto, M., Tamori, A., et al. (2021) Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduc-tion in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-On Combination Therapy. International Journal of Molecular Sciences, 22, 1456. https://doi.org/10.3390/ijms22031456
|
[19]
|
Zhou, K., Contag, C., Whita-ker, E., et al. (2019) Spontaneous Loss of Surface Antigen among Adults Living with Chronic Hepatitis B Virus Infec-tion: A Systematic Review and Pooled Meta-Analyses. The Lancet Gastroenterology & Hepatology, 4, 227-238. https://doi.org/10.1016/S2468-1253(18)30308-X
|
[20]
|
Kim, G.A., Lim, Y.S., An, J., et al. (2014) HBsAg Sero-clearance after Nucleoside Analogue Therapy in Patients with Chronic Hepatitis B: Clinical Outcomes and Durability. Gut, 63, 1325-1332.
https://doi.org/10.1136/gutjnl-2013-305517
|
[21]
|
Marcellin, P., Gane, E., Buti, M., et al. (2013) Regression of Cir-rhosis during Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B: A 5-Year Open-Label Follow-Up Study. The Lancet, 381, 468-475.
https://doi.org/10.1016/S0140-6736(12)61425-1
|
[22]
|
Kaur, S.P., Talat, A., Karimi-Sari, H., et al. (2022) Hepato-cellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg). Journal of Clinical Medicine, 11, 1126.
https://doi.org/10.3390/jcm11041126
|
[23]
|
Kim, G.A., Lee, H.C., Kim, M.J., et al. (2015) Incidence of Hepatocel-lular Carcinoma after HBsAg Seroclearance in Chronic Hepatitis B Patients: A Need for Surveillance. Journal of Hepa-tology, 62, 1092-1099.
https://doi.org/10.1016/j.jhep.2014.11.031
|
[24]
|
Alawad, A.S., Auh, S., Suarez, D., et al. (2020) Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen. Clinical Gastroenterology and Hepatology, 18, 700-709.e3. https://doi.org/10.1016/j.cgh.2019.07.018
|
[25]
|
Yoo, S., Kim, J.Y., Lim, Y.S., et al. (2022) Impact of HBsAg Seroclearance on Late Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resec-tion. Journal of Hepatology, 77, 939-946.
https://doi.org/10.1016/j.jhep.2022.05.014
|
[26]
|
Choi, J., Yoo, S. and Lim, Y.S. (2021) Comparison of Long-Term Clinical Outcomes between Spontaneous and Therapy-Induced HBsAg Seroclearance. Hepatology, 73, 2155-2166. https://doi.org/10.1002/hep.31610
|
[27]
|
Yip, T.C.F., Wong, V.W.S., Tse, Y.K., et al. (2021) Similarly Low Risk of Hepatocellular Carcinoma after either Spontaneous or Nucleos (t) Ide Analogue-Induced Hepatitis B Surface Antigen Loss. Alimentary Pharmacology & Therapeutics, 53, 321-331.
|